Lynn has multiple myeloma, a blood cancer in which ... reported to the hospital for two outpatient procedures. First, a PICC line was inserted in her arm. That would provide intravenous access ...

During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to ...

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

About 6,000 people in the UK are diagnosed with multiple myeloma each year. The new time-saving test is intended for people with MGUS (Monoclonal Gammopathy of Unknown Significance), a precursor ...

Blocking the chemokine receptor CCR1 can enhance the response of multiple myeloma cells to dexamethasone, a common treatment. High CCR1 levels are associated with poor outcomes and glucocorticoid ...

A four-drug regimen offers superior disease control and response depth in multiple myeloma compared to three-drug regimens ... until we learn if CAR-T or bi-specific T cell engagers can come to the ...

A study in patients with solid tumors found that CRBSI is significantly linked to mortality in patients with PICCs, whereas CRT and CRLC are not significant risk factors.

Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma ...

Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, prognosis, and therapeutic management of multiple myeloma. This new study in ...

Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, prognosis, and therapeutic management of multiple myeloma. This new study in ...